1055970-97-2

Upstream product

• 30766-22-4 methyl 5-hydroxy-3-pyridinecarboxylate 
• 4101-30-8 2-amino-4,5-dimethoxyacetophenone 
• 1055962-39-4 2-chloro-6,7-dimethoxy-4-methyl-quinoline-3-carbonitrile hydrochloride 
• 1055962-37-2 6,7-dimethoxy-4-methyl-2-oxo-1,2-dihydro-quinoline-3-carbonitrile 
• 1018909-03-9 tert-butyl 4-fluorobenzyl(2'-hydroxyethyl)carbamate 
• 1055962-40-7 6,7-dimethoxy-4-methyl-3-cyanoquinoline 
• 1055969-28-2 methyl 5-(2-(tert-butoxycarbonyl(4-fluorobenzyl)amino)ethoxy)nicotinate 

Downstream Products

• 1055964-22-1 tert-butyl-2-(5-(4-amino-8,9-dimethoxybenzo[c][2,7]naphthyridin-2-yl)pyridin-3-yloxy)ethyl(4-fluorobenzyl)carbamate 

Relevant academic research and scientific papers

BENZO[C][2,7]NAPHTHYRIDINE DERIVATIVES, AND THEIR USE AS KINASE INHIBITORS

The present invention relates to Benzo[c] [2,7] naph thy ri dine Derivatives of formula (I), compositions comprising an effective amount of a Benzo[c] [2,7]naphthyridine Derivative, methods for treating or preventing a proliferative disorder or an autoimmune disease, comprising administering to a subject in need thereof an effective amount of a Benzo[c] [2,7]naphthyridine Derivative, methods for modulating PDK-I activity, PKA activity, Akt activity, S6K activity, or PKC activity, comprising administering to a subject in need thereof an effective amount of a Benzo[c] [2,7] naphthyridine Derivative. The invention also relates to processes for preparing a Benzo[c] [2,7] naphthyridine Derivative.